Literature DB >> 18928481

Nesiritide following maze and mitral valve surgery.

Thomas M Beaver1, Almut Winterstein, Phillip J Hess, Tomas D Martin, George J Arnaoutakis, Yong G Peng, A Ahsan Ejaz.   

Abstract

BACKGROUND: Fluid retention following "maze" and mitral valve surgery has been associated with diminished levels of atrial natriuretic peptide (ANP). We hypothesized prophylactic administration of nesiritide (human recombinant brain natriuretic peptide, NES, Natrecor, Scios, Fremont, CA, USA), which has similar physiologic properties to ANP and would promote diuresis in maze and mitral patients postoperatively.
METHODS: Randomized, blinded, prospective pilot study comparing patients undergoing maze and mitral surgery including excision of the left atrial appendage. Three hours after cardiopulmonary bypass, patients received either a 72-hour infusion of NES at 0.01 mcg/kg/min (n = 9) or placebo (n = 10). Diuresis, diuretics, time to extubation, oxygenation, ANP, and serum Endothelin-1 levels were measured. Nonparametric analysis with Mann-Whitney test was performed with SPSS (SPSS Inc., Chicago, IL, USA).
RESULTS: In both groups, postoperative ANP levels fell from baseline (NES 330 to 280 ng/mL and control 220 to 150 ng/mL). There were no significant differences in patients receiving NES compared to controls in diuresis (1.33 mL/kg/hour urine output NES vs. 1.68 mL/kg/hour controls, p = 0.14); furosemide dosage (0.04 mg/kg/hour NES vs. 0.04 mg/kg/hour controls, p = 0.08); time to extubation (17.5 hours NES vs. 19.5 control, p = 0.42) or PaO2/FiO2 ratio at 48 hours (NES 200 vs. 273 control, p > 0.05). Endothelin-1 levels were higher at baseline with NES but not at 1 and 72 hours after cardiopulmonary bypass (NES 3.1, 3.8, 2.9 pg/mL vs. control 1.85, 4.05, 2.75 pg/mL; p = 0.01, 0.77, 0.47).
CONCLUSIONS: This pilot study did not demonstrate additional diuresis with nesiritide in postoperative mitral/maze patients already following a loop diuretic protocol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18928481     DOI: 10.1111/j.1540-8191.2007.00552.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  5 in total

1.  Effect of recombinant human brain natriuretic peptide on acute kidney injury after coronary artery bypass grafting: a retrospective comparative cohort study.

Authors:  Ziyao Wang; Yangyan Wei; Junyu Chen; Qian Zhang; Jiwen Tang; Qing Chang
Journal:  Ann Transl Med       Date:  2022-09

Review 2.  Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis.

Authors:  Chieko Mitaka; Toshifumi Kudo; Go Haraguchi; Makoto Tomita
Journal:  Crit Care       Date:  2011-10-27       Impact factor: 9.097

3.  Safety and efficacy of the perioperative administration of recombinant human brain natriuretic peptide (rhBNP): a systematic review and meta-analysis.

Authors:  Ping Hua; Jianyang Liu; Jun Tao; Xifeng Lin; Rongjun Zou; Dingwen Zhang; Songran Yang
Journal:  Ther Clin Risk Manag       Date:  2018-02-20       Impact factor: 2.423

4.  Effects of recombinant human brain natriuretic peptide in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis.

Authors:  Cheng Ning; Yawei Zheng; Jie Li; Ming Liu; Zhuyuan Fang
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

5.  Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis.

Authors:  Xuecheng Zhao; Da-Qi Zhang; Rongjing Song; Guoqiang Zhang
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.